Arcus Biosciences Announces That It Has Dosed Its First Subject In Arc-10, A Phase 3 Study, Co. Says Dosing Of First Subject Triggers Milestone Payments To Wuxi Biologics Of $10M And Abmuno Therapeuti
Arcus Biosciences Announces That It Has Dosed Its First Subject In Arc-10, A Phase 3 Study, Co. Says Dosing Of First Subject Triggers Milestone Payments To Wuxi Biologics Of $10M And Abmuno Therapeuti
Arcus Biosciences公司宣佈,它已經在Arc-10中給第一個受試者注射了劑量,這是一個第三階段的研究,公司説,第一個受試者的劑量將觸發向藥明生物和Abmuno治療公司支付1000萬美元的里程碑式的付款
Arcus Biosciences Announces That It Has Dosed Its First Subject In Arc-10, A Phase 3 Study, Co. Says Dosing Of First Subject Triggers Milestone Payments To Wuxi Biologics Of $10M And Abmuno Therapeuti
Arcus Biosciences公司宣佈,它已經在Arc-10中給第一個受試者注射了劑量,這是一個第三階段的研究,公司説,第一個受試者的劑量將觸發向藥明生物和Abmuno治療公司支付1000萬美元的里程碑式的付款
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。